Spadaro AG, et al. - Whether renal denervation would be a safe and feasible treatment option for patients with advanced symptomatic Chagas cardiomyopathy was assessed in this open-label prospective pilot study. Participants had severe symptomatic heart disease, with decidedly reduced left ventricular function. Renal denervation was performed in 11 patients and conservative treatment was received by 6 patients. A composite of all-cause mortality, myocardial infarction, stroke, requirement for renal artery invasive treatment, or deteriorating renal function defined major adverse events, the incidence of which at 9 months was assessed as the primary endpoint. In the renal denervation group and in the control arm, the occurrence of the primary endpoint after 9 months was reported in 36.4% and 50.0% of patients, respectively. Overall, findings revealed the safety as well as the feasibility of renal denervation in patients with Chagas cardiomyopathy.